Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The IL-17A–IL-17F inhibitor bimekizumab is safe and effective for the treatment of both radiographic and non-radiographic axial spondyloarthritis, according to the results of two parallel phase III trials.
Age-related stiffening of the extracellular matrix in cartilage promotes chondrocyte ageing in an epigenetically controlled process involving repression of the longevity protein α-Klotho.
Blockade of iron uptake by the transferrin receptor CD71 can reduce metabolic dysregulation in T cells, resulting in amelioration of autoimmune pathology in lupus-prone mice.
IL-37 can delay intervertebral disc degeneration in rats by regulating the NF-κB pathway and ameliorating the senescence phenotype of nucleus pulposus cells.
IKKε, an upstream regulator of the NF-κB signalling pathway, mediates cartilage degradation in a mouse model of osteoarthritis and is a potential therapeutic target.
New research suggests that impaired synovial lymphatic function contributes to the pathogenesis of age-related osteoarthritis and could represent a new therapeutic target.
A calcium-binding peptide derived from fetuin-A inhibited pathological cartilage calcification in an experimental model of osteoarthritis, suggesting therapeutic potential.
Lipid nanoparticles loaded with type II collagen and rapamycin can induce antigen-specific regulatory T cell responses and alleviate disease in a mouse model of osteoarthritis.
New evidence from animal models and human studies suggests that mammalian target of rapamycin has a role in the pathophysiology of Still’s disease and macrophage activation syndrome.
New research reveals that ferritin has an essential role in neutrophil extracellular trap (NET)-mediated inflammation, and suggests that NETs or the ferritin receptor MSR1 could be targeted for the treatment of adult-onset Still disease.
